ClinicalTrials.gg
CompletedNCT00446563Updated May 11, 2011Results posted

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

A Phase 3 interventional study of Valsartan and Amlodipine in Hypertension; Hypertrophy, Left Ventricular, sponsored by Novartis. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-05-11.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
98th of 139
90 · median 198
Started
2007
with 11 others
Phase 3
53 of 140
none open now
Registered
79th of 140
by date
Lead sponsor
69 of 140
Novartis

Among the 140 studies testing valsartan in Hypertension, this one is the 98th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 79th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy

03

Conditions studied

  • Hypertension; Hypertrophy, Left Ventricular

Keywords

  • Left ventricular hypertrophy, hypertension, valsartan, amlodipine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian; male or female outpatients and age between 18-80 years of age, inclusive.
  • Patients with a history of essential hypertension and who are actually treated either with an antihypertensive monotherapy and with a diastolic blood pressure >=90 and \<= 105mmHg or with a combination therapy (limited to two active compounds) and with a diastolic blood pressure of >=90 and \<= 100mmHg.
  • Patients with Left Ventricular Hypertrophy

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • Symptomatic heart failure
  • History of stroke, heart attack, coronary bypass surgery etc.
  • Insulin-dependent diabetes mellitus or poorly controlled diabetes mellitus.

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Amlodipine + Valsartan

    Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.

    Drug: Valsartan · Drug: Amlodipine

  • Active comparator
    Losartan + Hydrochlorothiazide

    Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.

    Drug: Hydrochlorothiazide · Drug: Losartan

Interventions

  • 160 mg film coated tablets taken orally once daily in the morning.

  • 5 mg or 10 mg tablets taken orally once daily in the morning.

  • 12.5 mg or 25 mg tablets taken orally once daily in the morning.

  • 100 mg tablets taken orally once daily in the morning.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)

    Time frame: Baseline to week 52

Secondary outcomes

  1. Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI

    Time frame: Baseline to week 52

  2. Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI

    Time frame: Baseline to week 52

  3. Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI

    Time frame: Baseline to week 52

  4. Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI

    Ejection fraction is a measurement of the percentage of blood that is pumped out of a filled ventricle with each heartbeat.

    Time frame: Baseline to week 52

  5. Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI

    Time frame: Baseline to week 52

  6. Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI

    Time frame: Baseline to week 52

  7. Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI

    Time frame: Baseline to week 52

  8. Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI

    Time frame: Baseline to week 52

  9. Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI

    Time frame: Baseline to week 52

  10. Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI

    Time frame: Baseline to week 52

  11. Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)

    Time frame: Baseline to week 52

  12. Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)

    Time frame: Baseline to week 52

  13. Percentage of Participants Achieving Target Blood Pressure at Week 52

    Target blood pressure defined as having a mean sitting systolic blood pressure (MSSBP) \< 140 mm Hg and a mean sitting diastolic blood pressure (MSDBP) \< 90 mm Hg.

    Time frame: Week 52

  14. Percentage of Participants Who Experienced Adverse Events (AEs)

    An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after obtaining informed consent even if the event was not considered to be related to study drug. Medical conditions/diseases present before obtaining informed consent were only considered adverse events if they worsened after study start. Abnormal laboratory values or test results constituted adverse events only if they induced clinical signs or symptoms, required study drug discontinuation or required therapy.

    Time frame: Baseline to week 52

07

Results

Posted Apr 27, 2011

Participant flow

Participant flow — Overall Study
MilestoneValsartan and AmlodipineLosartan and HCTZ
Started4347
Completed3638
Not completed79
Withdrew: Adverse event43
Withdrew: Abnormal laboratory value(s)01
Withdrew: Abnormal test procedure result(s)10
Withdrew: Unsatisfactory therapeutic effect03
Withdrew: Withdrawal by subject21
Withdrew: Administrative problems01

Outcome measures

PrimaryChange From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)
Time frame:
Baseline to week 52
Reported as:
Mean · g/m˄2
Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)
g/m˄2Valsartan and AmlodipineLosartan and HCTZ
Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)-7.1 ± 16.50-9.1 ± 18.89
SecondaryChange From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · g/m˄2
Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI
g/m˄2Valsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI-3.5 ± 7.4-4.4 ± 9.3
SecondaryChange From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · mm
Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI
mmValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI-1.1 ± 1.5-0.6 ± 1.3
SecondaryChange From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · mm
Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI
mmValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI-0.4 ± 1.1-0.3 ± 1.2
SecondaryChange From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI

Ejection fraction is a measurement of the percentage of blood that is pumped out of a filled ventricle with each heartbeat.

Time frame:
Baseline to week 52
Reported as:
Mean · Percentage
Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI
PercentageValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI-0.8 ± 6.7-0.4 ± 5.9
SecondaryChange From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · ml
Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI
mlValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI0.1 ± 19.9-6.4 ± 22.9
SecondaryChange From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · ml
Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI
mlValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI0.0 ± 9.6-3.0 ± 11.2
SecondaryChange From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · ml
Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI
mlValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI0.4 ± 10.3-1.5 ± 10.3
SecondaryChange From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · ml
Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI
mlValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI0.2 ± 5.1-0.8 ± 5.1
SecondaryChange From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · cm˄2
Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI
cm˄2Valsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI-0.6 ± 3.2-1.0 ± 4.5
SecondaryChange From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI
Time frame:
Baseline to week 52
Reported as:
Mean · mm
Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI
mmValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI0.1 ± 1.9-0.8 ± 1.6
SecondaryChange From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)
Time frame:
Baseline to week 52
Reported as:
Mean · pg/ml
Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)
pg/mlValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)-4.5 ± 56.41-40.1 ± 74.09
SecondaryChange From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)
Time frame:
Baseline to week 52
Reported as:
Mean · mg/l
Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)
mg/lValsartan and AmlodipineLosartan and HCTZ
Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)0.8 ± 6.09-2.1 ± 9.90
SecondaryPercentage of Participants Achieving Target Blood Pressure at Week 52

Target blood pressure defined as having a mean sitting systolic blood pressure (MSSBP) \< 140 mm Hg and a mean sitting diastolic blood pressure (MSDBP) \< 90 mm Hg.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Target Blood Pressure at Week 52
Percentage of participantsValsartan and AmlodipineLosartan and HCTZ
Percentage of Participants Achieving Target Blood Pressure at Week 5253.514.9
SecondaryPercentage of Participants Who Experienced Adverse Events (AEs)

An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after obtaining informed consent even if the event was not considered to be related to study drug. Medical conditions/diseases present before obtaining informed consent were only considered adverse events if they worsened after study start. Abnormal laboratory values or test results constituted adverse events only if they induced clinical signs or symptoms, required study drug discontinuation or required therapy.

Time frame:
Baseline to week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced Adverse Events (AEs)
Percentage of participantsValsartan and AmlodipineLosartan and HCTZ
Percentage of Participants Who Experienced Adverse Events (AEs)69.868.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan and Amlodipine—2/43 (4.7%)15/43 (34.9%)
Losartan and HCTZ—6/47 (12.8%)16/47 (34%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventValsartan and AmlodipineLosartan and HCTZ
CORONARY ARTERY DISEASECardiac disorders1/430/47
MYOCARDIAL INFARCTIONCardiac disorders1/430/47
HYDROCELECongenital, familial and genetic disorders1/430/47
CHOLECYSTITISHepatobiliary disorders1/430/47
METASTATIC NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/430/47
BRADYCARDIACardiac disorders0/431/47
TACHYCARDIACardiac disorders0/431/47
ABDOMINAL PAINGastrointestinal disorders0/431/47
ANAL HAEMORRHAGEGastrointestinal disorders0/431/47
DIARRHOEAGastrointestinal disorders0/431/47
Most frequent other events
Most frequent other events
EventValsartan and AmlodipineLosartan and HCTZ
NASOPHARYNGITISInfections and infestations3/437/47
BACK PAINMusculoskeletal and connective tissue disorders5/432/47
OEDEMA PERIPHERALGeneral disorders4/430/47
DIARRHOEAGastrointestinal disorders1/434/47
BRONCHITISInfections and infestations3/430/47
NAUSEAGastrointestinal disorders1/433/47
HEADACHENervous system disorders0/433/47
ECZEMASkin and subcutaneous tissue disorders2/433/47

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan and AmlodipineLosartan and HCTZTotal
Mean58.2 ± 12.257.2 ± 10.957.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan and AmlodipineLosartan and HCTZTotal
Female121325
Male313465
08

Study locations

1 site
  • 25 centers in Germany
    Ludwigshafen, Germany
09

References and documents

Publications

  • Bruder O, Jensen CJ, Bell M, Rummel R, Boehm G, Klebs S, Sieder C, Senges J. Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension. J Drug Assess. 2011 Dec 16;1(1):1-10. doi: 10.3109/21556660.2011.639418. eCollection 2012. PubMed 27536421 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2007
First posted
Mar 13, 2007
Start
Mar 2007
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Apr 27, 2011
Last update
May 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00446563
Lead sponsor
Novartis
First posted
Mar 13, 2007
Start date
Mar 2007
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Apr 27, 2011
Last update
May 11, 2011

Study contacts

Novartis
study chair · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine

Start the discussion